What's breaking now, across thousands of outlets.
Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Congo will receive 70,000 doses of the Ervebo vaccine, which has been effective in past Ebola outbreaks, the World Health Organization and partners said Thursday, announcing a step seen as a major…
Bacteria in lung tumors may boost the activation of innate immune cells in the presence of a common vitamin metabolite, according to a preclinical study by researchers from the Johns Hopkins Kimmel…
In this webinar, The post Is Targeted Protein Degradation the “Break” Neurology Needs? appeared first on GEN - Genetic Engineering and Biotechnology News .
Guinea-Bissau is facing its first outbreak of mpox, UN children's agency UNICEF said Thursday, voicing concern that half of suspected cases were affecting children and that the country is…
The Ervebo vaccine is licensed for use against Ebola virus, one of the viruses that cause Ebola disease, but not for Bundibugyo virus.
